OpenOnco
UA EN
План лікування Онко-вікі Туморборд

Onco Wiki / Тривожна ознака

Oligometastatic esophagogastric adenocarcinoma per OMEC-1 (OligoMetastatic Esophagogastri...

Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.

IDRF-OLIGOMET-DEFINITION
ТипТривожна ознака
Статуспереглянуто 2026-05-08 | очікує клінічного підпису
ХворобиDIS-ESOPHAGEAL DIS-GASTRIC
ДжерелаSRC-ESMO-ESOPHAGEAL-2024 SRC-ESMO-GASTRIC-2024 SRC-NCCN-ESOPHAGEAL-2025 SRC-NCCN-GASTRIC-2025 SRC-OMEC-1-KROESE-2023 SRC-RENAISSANCE-AIO-FLOT5

Походження тривожної ознаки

ВизначенняOligometastatic esophagogastric adenocarcinoma per OMEC-1 (OligoMetastatic Esophagogastric Cancer) European Delphi consensus (Kroese et al., Eur J Cancer 2023, PMID 36947929). Defined as ≤3 distant metastatic lesions amenable to local therapy in a patient with controllable primary disease and ECOG 0-1 fitness. Excluded scenarios: peritoneal carcinomatosis, leptomeningeal disease, >3 brain metastases. RENAISSANCE / AIO-FLOT5 trial (NCT02578368) eligibility narrower: ≤1 incurable organ-system involvement, no ascites, ≤1 retroperitoneal LN station — uses FLOT chemo ± surgical resection (gastrectomy/oesophagectomy + metastasectomy). Triggers MDT consideration of metastasis-directed local therapy (metastasectomy or SBRT) added to systemic chemo, and registration on RENAISSANCE-pattern trials where available.
Клінічний напрямintensify
Категоріяhigh-risk-biology

Логіка спрацьовування

{
  "all_of": [
    {
      "comparator": "<=",
      "finding": "distant_metastasis_count",
      "threshold": 3
    },
    {
      "comparator": "<=",
      "finding": "ecog_performance_status",
      "threshold": 1
    },
    {
      "finding": "primary_tumor_controllable",
      "value": true
    },
    {
      "finding": "all_metastatic_sites_amenable_to_local_therapy",
      "value": true
    }
  ],
  "none_of": [
    {
      "finding": "peritoneal_carcinomatosis",
      "value": true
    },
    {
      "finding": "leptomeningeal_disease",
      "value": true
    },
    {
      "finding": "brain_metastases_count_gt_3",
      "value": true
    }
  ],
  "type": "composite_score"
}

Нотатки

OMEC-1 consensus criteria (Kroese et al., Eur J Cancer 2023): 1. ≤3 distant metastatic lesions (primary numerical threshold). 2. Includes metachronous oligo-recurrence ≥6 months after curative- intent treatment. 3. Required diagnostic workup: PET/CT, EUS, brain MRI for symptomatic patients. 4. Required clinical fitness: ECOG 0-1, controllable primary, all metastatic sites amenable to local therapy (metastasectomy or SBRT). 5. Excluded: peritoneal carcinomatosis, leptomeningeal disease, >3 brain metastases. RENAISSANCE / AIO-FLOT5 (NCT02578368) eligibility is narrower than OMEC-1 consensus and represents the trial-grade cutoff: - ≤1 incurable organ-system involvement (e.g. liver-only OR retroperitoneal-LN-only). - No ascites. - ≤1 retroperitoneal lymph-node station. - Adequate response to induction FLOT before randomisation to surgery vs continued FLOT. Local-therapy entities (metastasectomy Surgery, SBRT RadiationCourse) for oligomet are future Phase C extensions — not yet in KB. RF triggers MDT review and routes to oligomet indications which describe sequence in notes/description text rather than typed phases (§17 phases skipped for v0.1; planning doc gi2_wave §4.5 + §17 ratifica...

Де використовується

Algorithms

Indications

Тривожна ознака